WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 27-May-2016 (Data received as of 20-May-2016)
Next overall update Fall 2016
2015 data are provisionary
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 7'0901 Infant (under 12 months) mortality rate: 132
GDP / capita (US$): 10'3951 Child (under 5 years) mortality rate: 142

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 185  184  182  181  179  157  138  118 
Births
Surviving infants
Pop. less than 5 years 14  14  14  14  14  16  18  17 
Pop. less than 15 years 43  43  44  44  44  51  50  52 
Female 15-49 years 50  50  50  49  49  41  33  26 

Number of reported cases

(Click for retrospective incidence data for Saint Lucia)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart
  30  35 
Mumps
ChartChart
 
Pertussis
ChartChart
  19 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Saint Lucia)
Vaccine year result method % card seen                                                
BCG          99*  89  99*  99*  99*  91  94  27 
DTP1          99*  99*  99*  99*  99*  76 
DTP3          99*  99  99*  98  99  70  89  56 
DTP4          83  85 
IPV1          21 
HepB_BD         
HepB3          99*  99  99*  98  99 
Hib3          99*  99  99*  98  99 
JapEnc         
MCV1          97  99*  99*  99*  91  88  82 
MCV2          95  79  62  80  72  89 
PCV1         
PCV3         
Pol3          99*  99  99*  98  99  70  90  58 
Rota1         
RotaC         
Rubella1          97  99*  99*  99*  91 
TT2plus          16 
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Saint Lucia)
BCG
ChartChart
  89  99  99  99  91  94  27 
DTP1
ChartChart
  99  99  99  99  76  96  79 
DTP3
ChartChart
  99  99  98  99  70  89  56 
HepB3
ChartChart
  99  99  98  99 
HepB_BD
ChartChart
 
Hib3
ChartChart
  99  99  98  99 
MCV1
ChartChart
  99  99  99  91  88  82 
MCV2
ChartChart
  79  62  80  72  89 
PCV3
ChartChart
 
Pol3
ChartChart
  99  99  98  99  70  90  58 
RotaC
ChartChart
 

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 6 weeks; Yes
DT 4-5 years; Yes
DTwP 18 months; Yes
DTwPHib 3, 5, 7 months; Yes Immunocompromised, infants of Hep B+ mothers
DTwPHibHepB 3, 5, 7 months; Yes
HIB 3, 5 months; at risk
HepB_Adult 12-40 years; Yes
HepB_Pediatric birth; 4 weeks; Yes Adolescents at risk
IPV 3, 5, 7, 18 months; 5, 11 years; Yes immunocompromised (routine dose from November 2015)
Influenza_Adult Yes chronic diseases and risk groups
MMR 1, 4-5 years; Yes
OPV 3, 5, 7, 18 months; 5, 11 years; Yes
Td 11 years; Yes
Tdap pertussis outbreak
Varicella Yes High risk
YF Yes Travelers

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number   2014-2015  2013-2014  2012-2013  2011-2012  2010-2011  2009-2010 
Nº of districts with microplans that include activities to raise immunization coverage number 36 

System performance

Total Nº districts in country number 36  36 
Nº districts with DTP3 coverage >=80% number 27  31 
% of districts with DTP3 coverage >=80% From 0 to 100% 75  86  100  89  78  67  89 
Nº districts with measles (MCV1) coverage >=95% number 20  19 
% of districts with MCV1 coverage >=95% From 0 to 100% 56  53  33  22  33  33  56 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  No  No     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 91  99  93  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No  No     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.